Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in -mutated colorectal cancer

Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in -mutated colorectal cancer

Background: KRAS is frequently mutated in the tumors of patients with metastatic colorectal cancer (mCRC) and thus represents a valid target for therapy. However, the strategies of targeting KRAS directly and targeting the downstream effector mitogen-activated protein kinase kinase (MEK) via monothe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Susmita Ghosh, Fan Fan, Reid Powell, Yong Sung Park, Clifford Stephan, E. Scott Kopetz, Lee M. Ellis, Rajat Bhattacharya
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-12-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359241303302
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
by: Rūta Čepulytė, et al.
Published: (2020-01-01)

Retraction Note: MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells
by: Lin Lin, et al.
Published: (2024-11-01)

Clinical response to dabrafenib plus trametinib in BRAF V600E mutated papillary craniopharyngiomas: a case report and literature review
by: Paul Hanona, et al.
Published: (2024-11-01)

GRHL3 Promotes Tumor Growth and Metastasis via the MEK Pathway in Colorectal Cancer
by: Lin Tan, et al.
Published: (2021-01-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
by: Eva Marie Erfurth, et al.
Published: (2024-12-01)

Cutaneous adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis
by: Junhui Qian, et al.
Published: (2024-12-01)

Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study
by: Malte Beckmann, et al.
Published: (2024-11-01)

Global trends and emerging insights in BRAF and MEK inhibitor resistance in melanoma: a bibliometric analysis
by: Jianhao Bai, et al.
Published: (2025-01-01)

Exceptional response to rechallenge of BRAF/MEK inhibitors in patients with primary acquired resistance to targeted therapy
by: B. Ziółkowska, et al.
Published: (2024-01-01)

Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors
by: Lucillia Bezu, et al.
Published: (2023-12-01)

MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1β through the MEK-Erk1/2 and Jak/Stat3 Pathways
by: Zeng-Qiao Zhang, et al.
Published: (2021-01-01)

Vitamin C and MEK Inhibitor PD0325901 Synergistically Promote Oligodendrocytes Generation by Promoting DNA Demethylation
by: Xinyue Ren, et al.
Published: (2024-12-01)

SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells
by: Melissa Bernhardt, et al.
Published: (2025-01-01)

MEK inhibitor PD0325901 upregulates CD34 expression in endothelial cells via inhibition of ERK phosphorylation
by: Chihiro Hosoda, et al.
Published: (2024-06-01)

Miraculous recovery in infantile refractory langerhan cell histiocytosis(LCH) with Trametinib and four-year follow-up
by: Vipin Khandelwal, et al.
Published: (2024-01-01)

The clinically relevant MEK inhibitor mirdametinib combined with D-cycloserine and prediction error disrupts fear memory in PTSD models
by: Sanket B. Raut, et al.
Published: (2024-12-01)

Real-world effectiveness of dabrafenib and trametinib in patients with BRAF-positive melanoma treated in routine Bulgarian clinical practice
by: Alexandra Savova, et al.
Published: (2024-12-01)

Refractory Chylothorax and Ventricular Hypertrophy Treated with Trametinib in a Patient with Noonan Syndrome: 18-Month Follow-Up
by: Antonia Pascarella, et al.
Published: (2024-10-01)

Dabrafenib plus trametinib in low-grade versus high-grade gliomas: a systematic review and meta-analysis
by: Bardia Hajikarimloo, et al.
Published: (2024-11-01)

Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma
by: Scott D. Schoenberger, et al.
Published: (2013-01-01)

Liquid Biopsy Monitoring in BRAF-V600E Mutated NSCLC Patients Treated With Dabrafenib Plus Trametinib: A Prospective, Explorative, Multicentric Study. LiBRA_study (GOIRC-03-2020)
by: M. Pluchino, et al.
Published: (2023-11-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
by: Antoni Ribas, et al.
Published: (2020-10-01)

The role of MEK inhibition in pediatric low-grade gliomas
by: Shehryar R. Sheikh, et al.
Published: (2024-12-01)

Paclitaxel-induced Hypersensitivity Reaction
by: Cyril Sajan, et al.
Published: (2024-12-01)

Modeling immune checkpoint inhibitor associated myocarditis in vitro and its therapeutic implications
by: Garrett Jensen, et al.
Published: (2024-12-01)

Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells.
by: Karsten Jürchott, et al.
Published: (2010-12-01)

A novel human specific lncRNA MEK6-AS1 regulates adipogenesis and fatty acid biosynthesis by stabilizing MEK6 mRNA
by: Di Li, et al.
Published: (2025-01-01)

RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway
by: Zhidong Huang, et al.
Published: (2024-11-01)

HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer
by: Xin Li, et al.
Published: (2025-01-01)

Study of a panel of genetic mutations in fibrocalcific pancreatic diabetes (FCPD): SPINK1 (N34S) mutation unlikely to be relevant
by: Vijay Budhwar, et al.
Published: (2024-12-01)

Proapoptotic role of CDK1 in overcoming paclitaxel resistance in ovarian cancer cells in response to combined treatment with paclitaxel and duloxetine
by: Gyeongmi Kim, et al.
Published: (2024-12-01)

Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance
by: Atsunori Ueyama, et al.
Published: (2016-01-01)

TIPE2 inhibits melanoma progression through MEK/ERK signaling
by: Xin Gao, et al.
Published: (2024-11-01)

A novel 4-(1,3,4-thiadiazole-2-ylthio)pyrimidine derivative inhibits cell proliferation by suppressing the MEK/ERK signaling pathway in colorectal cancer
by: Li Weiwei, et al.
Published: (2023-09-01)

EGFR inhibitors in the treatment of colorectal cancer
by: M. В. Zabelin, et al.
Published: (2018-09-01)

Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy
by: Xinyang Shen, et al.
Published: (2024-12-01)

Paclitaxel triggers molecular and cellular changes in the choroid plexus
by: Alemeh Zamani, et al.
Published: (2024-11-01)

p53 Mutations and DNA Ploidy in Colorectal Adenocarcinomas
by: Paola Campomenosi, et al.
Published: (1998-01-01)

Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
by: Michael Hoffmeister, et al.
Published: (2025-02-01)